Last $37.37 USD
Change Today -0.01 / -0.03%
Volume 184.1K
HAE On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

haemonetics corp/mass (HAE) Snapshot

Open
$37.39
Previous Close
$37.38
Day High
$37.61
Day Low
$37.03
52 Week High
12/9/13 - $44.20
52 Week Low
05/1/14 - $29.86
Market Cap
1.9B
Average Volume 10 Days
208.7K
EPS TTM
$1.51
Shares Outstanding
51.3M
EX-Date
--
P/E TM
24.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for HAEMONETICS CORP/MASS (HAE)

Related News

No related news articles were found.

haemonetics corp/mass (HAE) Related Businessweek News

No Related Businessweek News Found

haemonetics corp/mass (HAE) Details

Haemonetics Corporation is engaged in the design, development, manufacture, and marketing of automated blood component collection devices and surgical blood salvage devices in the United States and internationally. It provides various plasma products, including PCS brand plasma collection equipment and consumables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and blood center products comprising multicomponent collection system brand apheresis equipment to collect specific blood components integrated from the donor, automated cell processor brand solution to automate the washing and freezing of red cell components in the lab, and filtration products. The company also offers various hospital products, such as TEG thrombelastograph hemostasis analyzer system that measures a patient's hemostasis or the ability to form and maintain blood clots; Cell Saver system for cardiovascular surgery procedures; OrthoPAT surgical blood salvage system for orthopedic procedures; and IMPACT Online Web-based software platform that monitors and measures improvements in a hospital’s blood management practices. In addition, it offers SafeTrace Tx and BloodTrack suite of solutions, as well as El Dorado Donor donation and blood unit management systems. The company markets and sells its products to bio-pharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

3,782 Employees
Last Reported Date: 05/22/14
Founded in 1971

haemonetics corp/mass (HAE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $718.0K
President of Global Plasma
Total Annual Compensation: $588.9K
Executive Vice President of Global Manufactur...
Total Annual Compensation: $455.0K
Chief Science & Technology Officer
Total Annual Compensation: $441.0K
Compensation as of Fiscal Year 2014.

haemonetics corp/mass (HAE) Key Developments

Haemonetics Seeks Acquisitions

Haemonetics Corporation (NYSE:HAE) continues to repurchase shares and bolt-on acquisitions, said, Gerry Gould, Vice President of Investor Relations, Haemonetics Corporation.

Haemonetics Corporation Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 08:40 AM

Haemonetics Corporation Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 08:40 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom. Speakers: Gerard J. Gould, Vice President of Investor Relations.

Haemonetics Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended September 27, 2014; Reaffirms Earnings Guidance for the Fiscal Year 2015 and 2016

Haemonetics reported unaudited consolidated earnings results for the second quarter and six months ended September 27, 2014. For the quarter, the company's net earnings on a GAAP basis were $7.5 million, or $0.14 per diluted share, versus $16.5 million, or $0.32 per diluted share, a year earlier. On a non-GAAP basis, net income was $24.3 million, or $0.47 per diluted share, down from last year's $34.4 million, or $0.66 per diluted share. Revenues were $227.6 million, a decline from $235.8 million in the same period last year. Operating income was $12,407,000 against $23,430,000 a year ago. Income before taxes was $9,762,000 against $20,888,000 a year ago. GAAP cash flow from operations was $31,242,000 against $29,360,000 a year ago. Capital expenditures were $33,787,000 against $15,110,000 a year ago. Non-GAAP operating income was $35,144,000 against $49,006,000 a year ago. Non-GAAP income before taxes was $32,734,000 against $46,653,000 a year ago. For the six months, the company's net revenues were $452,068,000 against $455,297,000 a year ago. Operating income was $10,742,000 against $16,822,000 a year ago. Income before taxes was $5,554,000 against $11,639,000 a year ago. Net income was $3,839,000 or $0.07 dilution per share against $8,674,000 or $0.17 dilution per share a year ago. GAAP cash flow from operations was $44,980,000 against $42,762,000 a year ago. Capital expenditure was $70,872,000 against $28,202,000 a year ago. Non-GAAP operating income was $63,922,000 against $82,513,000 a year ago. Non-GAAP income before taxes was $59,193,000 against $77,640,000 a year ago. Non-GAAP net income was $44,093,000 or $0.85 dilution per share against $58,160,000 or $1.11 dilution per share a year ago. For fiscal year 2015, revenue is reaffirmed at a decline of 0-2%. Adjusted gross margin of approximately 50%, adjusted operating income of $140 million-$150 million, and adjusted earnings per share in the range of $1.85 to $1.95. Previous free cash flow guidance of approximately $120 million-$130 million, before funding restructuring and capital investment for transformation activities, is adjusted to approximately $100 million-$110 million. Elements impacting this change include higher solutions inventories and capital expenditures required to meet the needs of the new saline and sodium citrate contract announced this morning, and a ramp-up of Plasma devices to support anticipated growth. The company reiterates its expectations of returning to a mid-single digit revenue growth rate and double digit adjusted operating income and earnings per share growth rates in fiscal 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HAE:US $37.37 USD -0.01

HAE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cerner Corp $63.70 USD +0.69
Fresenius SE & Co KGaA €43.60 EUR +0.023
McKesson Corp $208.24 USD -0.70
Medtronic Inc $73.48 USD +0.69
Terumo Corp ¥2,700 JPY +21.00
View Industry Companies
 

Industry Analysis

HAE

Industry Average

Valuation HAE Industry Range
Price/Earnings 64.5x
Price/Sales 2.1x
Price/Book 2.3x
Price/Cash Flow 63.3x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HAEMONETICS CORP/MASS, please visit www.haemonetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.